Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get trading ideas, historical data, advanced options screeners, more. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Seagen Inc (SGEN)

Seagen Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,243,618
  • Shares Outstanding, K 184,435
  • Annual Sales, $ 1,574 M
  • Annual Income, $ -674,470 K
  • 60-Month Beta 0.67
  • Price/Sales 16.30
  • Price/Cash Flow N/A
  • Price/Book 8.66
Trade SGEN with:

Options Overview Details

View History
  • Implied Volatility 57.19% ( -0.22%)
  • Historical Volatility 29.65%
  • IV Percentile 71%
  • IV Rank 57.53%
  • IV High 74.87% on 06/06/22
  • IV Low 33.24% on 10/29/21
  • Put/Call Vol Ratio 0.55
  • Today's Volume 178
  • Volume Avg (30-Day) 2,949
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 59,172
  • Open Int (30-Day) 64,068

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.90
  • Number of Estimates 10
  • High Estimate -0.62
  • Low Estimate -1.07
  • Prior Year -1.61
  • Growth Rate Est. (year over year) +44.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
134.44 +1.81%
on 09/29/22
155.86 -12.18%
on 09/09/22
-15.47 (-10.15%)
since 09/02/22
3-Month
134.44 +1.81%
on 09/29/22
183.00 -25.21%
on 07/07/22
-39.90 (-22.57%)
since 07/05/22
52-Week
105.43 +29.82%
on 05/09/22
192.79 -29.00%
on 11/08/21
-35.82 (-20.74%)
since 10/05/21

Most Recent Stories

More News
Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?

Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.

SNY : 39.82 (-0.75%)
RHHBY : 41.7300 (-1.65%)
SGEN : 136.87 (-1.65%)
LVTX : 3.61 (+1.40%)
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223

Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.

RHHBY : 41.7300 (-1.65%)
SGEN : 136.87 (-1.65%)
APTO : 0.5865 (-2.25%)
LVTX : 3.61 (+1.40%)
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage global...

ZLAB : 37.07 (+1.28%)
SGEN : 136.87 (-1.65%)
GMAB : 35.74 (+0.82%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

LVTX : 3.61 (+1.40%)
SGEN : 136.87 (-1.65%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 136.87 (-1.65%)
LVTX : 3.61 (+1.40%)
Worried About the Stock Market? Take Warren Buffett's Advice and Do This

The billionaire investor is a big believer in betting on America.

ORCL : 66.64 (+1.45%)
SGEN : 136.87 (-1.65%)
TMUS : 141.23 (-0.92%)
KO : 56.24 (-0.95%)
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication

FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.

RHHBY : 41.7300 (-1.65%)
SGEN : 136.87 (-1.65%)
APTO : 0.5865 (-2.25%)
ORIC : 3.08 (-2.22%)
Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen Inc. (Nasdaq: SGEN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) seeking accelerated approval for...

SGEN : 136.87 (-1.65%)
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Sector ETF report for FBT

FBT : 138.68 (+0.02%)
UTHR : 212.05 (-1.66%)
IBB : 122.87 (+0.18%)
SGEN : 136.87 (-1.65%)
GRFS : 6.56 (-4.37%)
XBI : 82.67 (-0.40%)
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer

Seagen Inc. (Nasdaq:SGEN), Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced...

SGEN : 136.87 (-1.65%)
MRK : 88.39 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Seagen, Inc., a biotechnology company, focuses on developing & commercializing therapies targeted for the treatment of cancer. Adcetris, a lead FDA approved marketed product at Seagen, is used for treating Hodgkin lymphoma, certain T-cell lymphomas, other cancers in the U.S., Europe & several countries....

See More

Key Turning Points

3rd Resistance Point 142.00
2nd Resistance Point 140.12
1st Resistance Point 138.49
Last Price 136.87
1st Support Level 134.99
2nd Support Level 133.11
3rd Support Level 131.48

See More

52-Week High 192.79
Fibonacci 61.8% 159.42
Fibonacci 50% 149.11
Fibonacci 38.2% 138.80
Last Price 136.87
52-Week Low 105.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar